Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
EBD Group: Carola Schropp




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: EBD Group: Carola Schropp
Released on: August 21, 2008. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this interview, filmed at Bio-Europe Madrid, Fintan Walton talks to Carola Schropp, President and founder of the EBD Group. EBD has organised the partnering conference Bio-Europe since 1993 to enable networking between Pharmaceutical and Biotech companies and in September 2008 will launch BioPharm America. Carola Schropp discusses changes in this fast-growing industry, the ideas behind Bio-Europe and the part that such conferences play in deal making processes.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
EBD Group enters into conference making
Fintan Walton:
Hello and welcome to PharmaVentures Business Review with the special interview with Carola Schropp, who is the President and Founder of the EBD Group. Welcome to the show.
Carola Schropp:
Thanks for having me.
Fintan Walton:
Carola Schropp, your organization has built a good reputation for partnering conferences. How did EBD Group get into conference making?
Carola Schropp:
Well actually it was we found that we, I use to go to a lot of conferences in the United States and founded really easy to network with people, you just go get up and talk to somebody and I found the Europeans are little more stiff, they use to hang out in groups and it was hard to break in and so it's really a personal experience. And I decided we needed a more formal way of getting people together. So if you put them at a table then they talk to each other but they won't go up or get up and talk to somebody.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Carola Schropp
President and founder
Ms Carola Schropp founded the EBD Group in January of 1993. In the past 10 years, Ms. Carola Schropp has built EBD Group into one of the leading business development organizations using conferences as a venue to facilitate partnerships. For more than 20 years, Carola Schropp has been a strategic planning and business development consultant to technology firms. In 1995, she started the BIO-Europe Conference together with BIO,Biotechnology Industry Association to provide a forum for the Biotechnology and the Pharma industry to get together. Before EBD, Carola Schropp worked for other consulting companies including as Managing Director of ExperConsult, Inc., and Marketing Director at European Marketing and Sales (EMS) LTD. a consulting company headquartered in London. From 1985 to 1989 she held consultant and senior consultant positions at International Data Corporation in Framingham, MA. Ms Carola Schropp has written a number of articles published in industry publications, such as Nature Biotechnology, BioEntrepreneur, Genetic Engineering News, BioPharm, GIT, and BioCommerce Data Ltd.
EBD Group
EBD Group The leading firm for partnering in the life sciences, EBD Group organizes and mark conferences for the biotechnology and pharmaceutical industries. Building on this expertise, and with an unrivaled access to major players in these markets, EBD Group provides partnering services to other event organizers, and hands-on business development consultancy to support strategic partnering worldwide. EBD Groupoperates from offices in North America and Europe. Since the firm's inception in 1993, EBD Group's people have been partnering experts, driving together biotech innovation with the muscle of big pharma, where partnerships, as much as products, are generating spectacular growth.